Leaps by Bayer and Hitachi Ventures led the $130m Series C round in Huma Therapeutics, a global health technology company, with participation from Samsung Next, Sony Innovation Fund, Unilever Ventures and HAT. "This is a pivotal moment in Huma's development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives. We're already demonstrating how 'hospital at home' can transform healthcare, and how decentralized clinical trials can advance research in ways that weren't imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide," Dan Vahdat, Huma Founder and CEO.